International Brachytherapy (IBt) is planting the seeds of future health and vitality. IBt develops and markets interstitial implants -- commonly referred to as seeds -- used in brachytherapy to treat cancer. The radiotherapeutic implants are inserted inside or near cancerous tissue, delivering radioactive doses to tumors while sparing surrounding tissue. Founded in 1996, IBt operates from its Belgian headquarters as well as a US subsidiary, IBt Inc., and UK subsidiary IBt ltd. It also owns a majority stake in medical components provider Urorad GmbH.

pSivida Corp. company was founded in 1987 and is based in Watertown, Massachusetts. pSivida Corp., together with its subsidiaries, develops drug delivery products in the healthcare sector. It develops products utilizing its proprietary technologies, including Durasert, BioSilicon, CODRUG, and Medidur. The company's products include Retisert for the treatment of posterior uveitis; and Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis. Its products also include Iluvien, a Phase III clinical trial product for the treatment of diabetic macular edema; and Durasert and Iluvien, which are under pre-clinical trials to treat retinitis pigmentosa and age-related macular degeneration. In addition, pSivida Corp. owns the rights to develop and commercialize a modified form of silicon, known as BioSilicon, which has therapeutic applications for treatment of cancer. Its lead BioSilicon product is BrachySil, which is in Phase II clinical trial for the treatment of pancreatic cancer. The company primarily operates in the United Kingdom and the United States. It has strategic collaborations with Chiron Vision Corporation; Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited.

Vermillion, Inc. is involved in the discovery, development and commercialization of diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers (known as translational proteomics) for developing a procedure to measure a property or concentration of an analyte (known as an assay) and commercializing diagnostic tests. Vermillion has focuses in the areas of oncology, hematology, cardiology and women’s health. Vermillion’s focus on translational proteomics enables it to address the market for diagnostic tests that measure multiple protein biomarkers. In January 2010, the Company emerged from protection under Chapter 11 of the United States Bankruptcy Code.

PML Microbiologicals, Inc. company was founded in 1969 and is headquartered in Wilsonville, Oregon. It has manufacturing facilities in Mississauga, Canada; and Portland, Oregon. As of December 8, 2008, PML Microbiologicals, Inc. operates as a subsidiary of BioMérieux S.A. PML Microbiologicals, Inc. manufactures culture media and microbiological products for clinical and industrial applications in North America. It offers prepared culture media, stains, reagents, quality control organisms, sterility products, and collection and transport systems, as well as accessories for microbiology laboratories. The company also provides custom products, such as minimum inhibitory concentration panels, parasitology kits, diluents, and rinsing fluids. It serves clinical, pharmaceutical, research, environmental, personal care, and food and beverage industries. PML Microbiologicals, Inc. was formerly known as Prepared Media Laboratory.

Forest Pharmaceuticals, Inc. (FPI) can help you see the pharmaceuticals amidst the trees. The company develops, manufactures, and distributes a variety of prescription and OTC pharmaceutical products, including both branded and generic versions. Its product line includes Aerobid (asthma), Celexa and Lexapro (depression), Cervidil (cervical ripening), Tiazac (hypertension), and Namenda (Alzheimer's disease). FPI's products are marketed to physicians, hospitals, pharmacies, and managed care organizations in the US and Puerto Rico. The company, which operates manufacturing and packaging facilities in Missouri and Ohio, is a subsidiary of Forest Laboratories.

Upsher-Smith Laboratories, Inc. was founded in 1919 and is headquartered in Minneapolis, Minnesota with a facility in Denver, Colorado. Upsher-Smith Laboratories, Inc., a pharmaceutical company, engages in developing, manufacturing, commercializing, marketing, and distributing prescription and over-the-counter products. It offers drugs for cardiology, women's health, dermatology, neurology, and epilepsy and Parkinson's diseases. The company also provides prenatal vitamins. It serves patients, physicians, pharmacists, and healthcare organizations.

AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal treatment, as well as herbal remedies, vitamins and adjunctive therapies. Through its wholly owned subsidiary, AXM Pharma Shenyang, Inc., the Company has established a pharmaceutical operation focused on supplying the drugs and branded products in specific categories. Werke Pharmaceuticals, Inc. is the Company’s wholly owned subsidiary, which owns 100% of AXM Pharma Shenyang Inc., a wholly foreign owned enterprise (WFOE). Its product portfolio includes Asarone injectibles solution, Weifukang and Lifupeng. Weifukang is an antiseptic cream for cleansing acne and for relieving the symptoms of eczema, psoriasis and other skin irritations, such as contact dermatitis. Lifupeng (Rifampicin) is used for treatment of tuberculosis.

Targeted Genetics is putting the bull's-eye on disease. The drug developer is working in the promising (though as yet unproven) field of gene therapies, drugs that deliver particular DNA sequences into targeted cells to encourage (or sometimes inhibit) the production of proteins associated with disease. The company's drug candidates -- targeting conditions such as retinal dystrophies, lateral sclerosis, HIV/AIDS, heart failure, and Huntington's disease -- employ proprietary technology using bio-engineered viral cells (called vectors) to deliver the genes. The company is working on its own to develop therapies for certain candidates and with development partners on some other programs.

Nanospectra Biosciences, Inc. was founded in 2002 and is based in Houston, Texas. Nanospectra Biosciences, Inc., a medical device company, engages in developing and commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors. The company provides AuroLase Therapy, a medical device that is applicable to the ablation of various solid tumors. It also offers research-use-only nanoparticles with specific optical characteristics.

Third Wave Technologies is riding the biotech breakers. Using its Invader technology, Third Wave develops molecular diagnostic tests that detect genetic variations associated with a variety of conditions, including cystic fibrosis, cardiovascular risk factors, and infectious disease. Some tests can determine a patient's likely response to certain drugs, making it possible for doctors to avoid prescribing a drug that might cause dangerous side effects. Third Wave company has a strong presence in Japan, where it has a collaboration agreement with genetic researchers at the University of Tokyo. Third Wave Technologies was acquired by Hologic in 2008 for $580 million.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.